JPMorgan downgraded Afya to Neutral from Overweight with a price target of $23, up from $22. The analyst cites mostly valuation for the downgrade post the Q3 results. The firm believes current share prices reflect well the improvement in the medical regulatory environment.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on AFYA:
